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(x2 5 4.4, P , 0.05). Of the eight patients in the treatmentACEI/ATRA therapy decreases proteinuria by improving glo-
group who improved their renal function, three normalizedmerular permselectivity in IgA nephritis.
their renal function compared with one from the control group.Background. It has been postulated that angiotensin-convert-
Conclusion. Our data suggest that ACEI/ATRA therapying enzyme inhibitor/angiotensin receptor antagonist (ACEI/
may be beneficial in patients with IgAN with renal impairmentATRA) may decrease proteinuria in patients with glomerulo-
and nonselective proteinuria, as such patients may respond tonephritis by its action on the glomerular basement membrane.
therapy with improvement in protein selectivity, decrease inWe therefore studied the relationship between the response
proteinuria, and improvement in renal function. ACEI/ATRAof patients with IgA nephritis (IgAN) to ACEI/ATRA therapy
therapy probably modifies pore size distribution by reducingby decreasing proteinuria and its effect on the selectivity index
the radius of large unselective pores, causing the shunt pathway(SI) in these patients.
to become less pronounced, resulting in less leakage of proteinMethods. Forty-one patients with biopsy-proven IgAN en-
into the urine.tered a control trial, with 21 in the treatment group and 20 in
the control group. The entry criteria included proteinuria of 1 g
or more and/or renal impairment. Patients in the treatment
group received ACEI/ATRA or both with three monthly in-
Patients with IgA nephritis have nonselective protein-creases in dosage. In the control group, hypertension was
uria [1, 2]. It has also been previously reported that thetreated with atenolol, hydrallazine, or methyldopa. The follow-
ing tests were performed at three monthly intervals: serum selectivity index (SI) can be used as a prognostic index
creatinine, total urinary protein, SI, sodium dodecyl sulfate- in IgA nephritis (IgAN) [3, 4]. There is no definitive
polyacrylamide gel electrophoresis (SDS-PAGE), and low mo- therapy for IgAN, and many patients run a progressivelecular weight (LMW) proteinuria.
course of renal deterioration to end-stage renal failure,Results. After a mean duration of therapy of 13 6 5 months,
unlike patients with selective proteinuria like minimalin the treatment group, there was no significant change in
serum creatinine, proteinuria, or SI, but in the control group, change disease. One of the causes of renal deterioration
serum creatinine deteriorated from 1.8 6 0.8 to 2.3 6 1.1 mg/dL is now believed to be due to the tubulotoxic effect of
(P , 0.05). Among the 21 patients in the treatment group, 10
proteinuria [5]. In minimal change disease, in contrastresponded to ACEI/ATRA therapy determined as a decrease
to IgAN, although the protein load in the renal tubulesin proteinuria by 30% (responders), and the other 11 did not
respond (nonresponders). Among the responders, SI improved is heavier, it is only for a short duration since minimal
from a mean of 0.26 6 0.07 to 0.18 6 0.07 (P , 0.001), indicating change disease is responsive to steroids, unlike IgAN,
a tendency toward selective proteinuria. This was associated where patients are subject to long-term tubulotoxic ef-
with an improvement in serum creatinine from mean 1.7 6 0.6
fects of proteinuria resulting in gradual loss of renalto 1.5 6 0.6 mg/dL (P , 0.02) and a decrease in proteinuria
function.from a mean of 2.3 6 1.1 to 0.7 6 0.5 g/day (P , 0.001). After
treatment, proteinuria in the treatment group (1.8 6 1.6 g/day) Angiotensin-converting enzyme inhibitor/angiotensin
was significantly less than in the control group (2.9 6 1.8 receptor antagonist (ACEI/ATRA) has been employed
g/day, P , 0.05). The post-treatment SI in the responder group to treat the majority of patients with chronic progressive(0.18 6 0.07) was better than that of the nonresponder group
renal disease associated with proteinuria in an attempt(0.33 6 0.11, P , 0.002). Eight out of 21 patients in the treat-
to retard the progression to renal failure. The theory be-ment group who had documented renal impairment had im-
proved renal function compared with two in the control group hind this form of therapy is that ACEI/ATRA causes ef-
ferent arteriolar vasodilation of the glomerulus, thereby
decreasing the intraglomerular hypertension causing theKey words: protein selectivity, IgA nephropathy, angiotensin receptor
antagonist, ACE inhibitor, renal failure. proteinuria. This is referred to as nonimmunological
therapy to reduce hyperfiltration.Received for publication March 1, 2000
However, there have been studies to show that ACEIand in revised form May 25, 2000
Accepted for publication June 15, 2000 also reduces proteinuria in patients with insulin-depen-
dent diabetes mellitus (IDDM) by reducing the size ofÓ 2000 by the International Society of Nephrology
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large unselective pores in the glomerular basement mem- hypotension. Patients who could not tolerate the side
effect of cough caused by enalapril were converted tobrane (GBM) [6].
Angiotensin-converting enzyme inhibitor in animals losartan; 5 mg of enalapril are equivalent to 50 mg of
losartan. The cost of enalapril locally is half that of losar-and humans reduces the log-normal component of the
assumed pore size distribution [7] and more importantly tan, but some of our patients suffer from a dry cough
while on enalapril. On entry into the trial, patients werecauses the shunt pathway to become less pronounced by
reducing the radius of large unselective pores [8]. given a choice of either enalapril or losartan after being
told of the side effect of enalapril. Patients who couldIn the present study, we decided to investigate the
effects of ACEI/ATRA therapy in patients with IgA afford losartan tended to choose it. There were eight
patients on ACEI alone and eight on ATRA alone, andnephritis to see whether ACEI/ATRA therapy could
modify the SI of these patients and whether this modifi- five patients were on a combination of ACEI and ATRA.
A decrease of proteinuria by 30% or more was definedcation of SI was associated with a change in protein
excretion and renal function in these patients. as response to therapy.
Patients had the following investigations performed at
three monthly intervals: serum creatinine, total urinary
METHODS
protein (TUP), SI (the ratio of IgG clearance over trans-
During the period from December 1997 to December ferrin clearance), sodium dodecyl sulfate-polyacrylamide
1999, 41 patients with biopsy-proven primary IgA ne- gel electrophoresis (SDS-PAGE), and low molecular
phritis entered a randomized controlled trial, with 21 in weight (LMW) proteinuria, namely urinary a1-microglob-
the treatment group and the other 20 in the control ulin (a1m) and retinol-binding protein (RBP). Assay
group. Entry criteria included proteinuria of 1 gram or methodologies have been described previously [4]. Es-
more and or renal impairment defined as serum creati- sentially, creatinine was quantitated with alkaline picrate
nine .1.4 mg/dL. Those with serum creatinine .5.0 and TUP was quantitated by biuret reagent. SDS-PAGE
mg/dL were excluded or withdrawn from the trial. In was performed on the PhastSystem (Pharmacia, Upp-
the 21 patients with IgA nephritis on treatment, there sala, Sweden) using precast gel. Measurement of IgG
were 11 patients with hypertension and 15 with renal and transferrin in urine and serum was done by radial
impairment. In the control group, there were 9 patients immunodiffusion (RID) in agarose gel for SI calculation.
with hypertension and 13 with renal impairment. There The following LMW proteins, urinary a1m and RBP were
were no significant differences in the various parameters also estimated by RID using a urine with high LMW
between the treatment and control group on entry into protein content as standard so that results were ex-
the trial. None of the patients were on calcium channel pressed in arbitrary units (AU).
blockers, which may affect proteinuria, and all had well-
controlled blood pressure [systolic blood pressure (BP) Statistics
,150 mm Hg, diastolic BP ,90 mm Hg] during the study Sample size. Controlling for type I error of 5% and
period. Also, none were on steroids, cyclophosphamide, taking a power of 80% (that is, type II error of 20%),
or cyclosporine A. In the control group, hypertension assuming the success will increase from 0 to 40% moving
was treated with atenolol, hydrallazine, or methyldopa. from control to treatment group, 16 patients would need
All patients were given advice on a low-salt diet. None to be recruited in each group. It was decided to recruit
of the patients in the control as well as the treatment around 40 patients to allow for patients who may drop
groups were on treatment with aspirin, warfarin, dipyri- out of the trial.
damole, steroids, and cytotoxic drugs before and during Results were expressed as mean 6 SD. The t-test and
the study. Pearson’s chi-square were used for comparing data be-
The patients in the treatment group were treated with tween groups. Paired t-test was used to compare data
ACEI/ATRA or both and were reviewed at three obtained before and after treatment.
monthly intervals. The dose of ACEI/ATRA was in-
creased if necessary at three monthly intervals. Patients
RESULTSwere initially prescribed 5 mg enalapril (ACEI) or 50 mg
losartan (ATRA), which was increased to 10 mg or 100 Table 1 compares the serum creatinine, proteinuria,
and SI in the treatment and control group before andmg, respectively, after three months if proteinuria had
not decreased by 30%. The maximum dose we have after the study. In the treatment group, there was no
significant change in serum creatinine, proteinuria, orprescribed in the study for a patient was 10 mg of enala-
pril plus 100 mg of losartan. The dose of ACEI or ATRA SI, but in the control group, serum creatinine deterio-
rated from 1.8 6 0.8 to 2.3 6 1.1 mg/dL (P , 0.05) withwas decreased if a patient complained of giddiness. One
patient with normal BP could tolerate the maximum dose proteinuria increasing from 2.1 6 1.1 to 2.9 6 1.8 g/day
(P , 0.02). There was no significant change in SI. Amongof 10 mg ACEI and 100 mg losartan without giddiness or
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Table 1. Data of each patient with IgA nephropathy
Serum Urinary
creatinine protein Selectivity
TrialFollow-up Age mg/dL g/day index
Case Sex Hypertension Dosage duration
no. F/M Y/N Drug mg months Before After Before After Before Afteryears
Control group
1 16 34 M N — — 9 2.4 3.1 2.3 2.7 0.19 0.32
2 7 32 F N — — 12 2.4 1.0a 2.6 2.1 0.34 0.14
3 8 36 M Y A 100 9 4.5 2.9a 1.4 3.6 0.23 0.26
4 9 36 F Y P, M 80, 120 12 1.9 3.6 1.1 2.4 0.47 0.51
5 14 44 M Y A 50 12 1.6 2.6 1.5 1.9 0.14 0.24
6 10 29 M Y A 50 9 2.2 2.6 1.0 2.8 0.27 0.30
7 16 40 M Y P 80 12 1.9 3.2 1.0 1.8 0.25 0.32
8 14 37 M N — — 12 1.5 3.0 4.4 8.8 0.21 0.26
9 13 32 M N — — 15 1.6 1.7 1.1 2.0 0.21 0.20
10 5 36 M Y M 750 9 1.6 2.2 1.6 3.2 0.19 0.24
11 14 34 M N — — 6 1.4 1.5 4.5 5.4 0.22 0.13
12 11 27 M N — — 6 1.0 1.0 2.6 2.3 0.16 0.37
13 10 49 M Y P, H 120, 120 12 2.1 4.4 1.2 3.2 0.13 0.22
14 9 38 M N — — 15 2.2 3.2 4.2 3.6 0.15 0.12
15 7 38 M N — — 18 1.4 1.5 2.5 1.5 0.29 0.21
16 12 50 M Y A, H 50, 120 15 2.0 3.5 2.4 2.7 0.22 0.34
17 7 28 F N — — 18 0.9 0.8 1.3 1.7 0.29 0.19
18 10 45 F N — — 18 1.1 1.0 1.5 0.4 0.31 0.10
19 9 43 M N — — 21 1.4 1.4 1.2 1.6 0.37 0.22
20 9 34 F Y A 50 6 0.7 0.9 2.7 3.5 0.23 0.09
mean 11 37 12 1.8 2.3 2.1 2.9 0.24 0.24
6SD 3 6 4 0.8 1.1 1.1 1.8 0.08 0.10
Treatment groups
Responders (.30% TUP reduction, N 5 10)
1 9 30 M N ATRA 50 6 1.1 1.1 1.0 0.1 0.14 0.10
2 9 47 M Y ACEI 5 9 1.9 1.3a 1.2 0.6 0.22 0.11
3 11 40 M Y ATRA 150 18 2.3 2.2 3.6 1.1 0.35 0.26
4 16 39 F Y ACEI/ATRA 10/100 18 1.6 1.1a 1.6 1.0 0.31 0.24
5 10 27 M Y ATRA 50 21 2.0 1.7a 1.9 0.1 0.25 0.20
6 11 42 F Y ATRA 50 12 2.9 2.6a 3.1 1.2 0.28 0.18
7 3 29 F N ATRA 50 12 0.9 0.8 1.4 0.3 0.27 0.09
8 3 38 M N ACEI 15 9 1.7 1.6 4.1 1.7 0.21 0.16
9 3 38 F N ATRAb 100 12 1.4 1.3 3.2 0.5 0.38 0.31
10 16 48 F N ATRAb 50 6 1.0 1.0 2.2 0.6 0.22 0.12
mean 9 38 12 1.7 1.5 2.3 0.7 0.26 0.18
6SD 5 7 5 0.6 0.6 1.1 0.5 0.07 0.07
Nonresponders (,30% TUP reduction, N 5 11)
1 33 53 M Y ATRA 50 18 4.2 5.9 5.5 4.6 0.46 0.46
2 13 43 F Y ACEI/ATRA 5/100 15 1.9 3.0 1.4 6.4 0.36 0.44
3 19 55 F N ACEI 10 6 1.4 1.4 1.3 1.7 0.21 0.41
4 5 35 F N ACEI 10 12 1.3 0.8 1.8 1.9 0.16 0.19
5 20 40 M Y ACEI 10 12 2.2 2.0a 1.5 1.4 0.33 0.20
6 20 45 M Y ACEI 10 6 1.8 1.5a 1.5 1.6 0.40 0.37
7 15 30 M Y ACEI/ATRA 10/100 21 1.7 2.7 1.0 2.7 0.27 0.24
8 5 26 M N ACEI 10 6 3.9 4.9 2.0 2.6 0.18 0.19
9 10 46 F Y ACEI/ATRA 10/100 18 1.8 1.3a 4.2 4.7 0.35 0.32
10 4 18 M N ACEI 10 12 2.3 1.5a 1.3 1.3 0.33 0.43
11 16 59 M N ACEI/ATRA 10/100 15 2.3 2.3 1.5 1.4 0.32 0.38
mean 15 41 13 2.3 2.5 2.1 2.8 0.31 0.33
6SD 9 13 5 0.9 1.6 1.4 1.7 0.09 0.11
Abbreviations are: A, atenolol; P, propanolol; H, hydrallazine; M, methyldopa; ACEI, ACE inhibitor; ATRA, angiotensin receptor antagonist.
a Those who had an improved renal function
b Only 2 patients in study who converted from ACEI to ATRA
the 21 patients with IgAN in the treatment group, 10 Among the responders, the SI improved from a mean
of 0.26 6 0.07 to 0.18 6 0.07 (P , 0.001), indicating aresponded to ACEI/ATRA therapy determined as a de-
crease in proteinuria by 30% (responders), and the other tendency toward selective proteinuria. This was associ-
ated with an improvement in serum creatinine from a11 did not (nonresponders). Table 1 also compares the
results of therapy in the responders and nonresponders mean of 1.7 6 0.6 to 1.5 6 0.6 mg/dL (P , 0.02), a
decrease in proteinuria from a mean of 2.3 6 1.1 to 0.7 6after a mean duration of therapy for 13 6 5 months.
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Table 2. Comparing data between groups
Treatment Treatment
Control Treatment Responders Nonresponders
(N 5 20) (N 5 21) (N 5 10) (N 5 11)
Sex M:F 15:5 12:9 5:5 7:4
Age years 3766 39610 3867 41 613
Follow-up years 1163 1267 965 1569
Trial duration months 1264 1365 1265 13 65
Hypertension Yes:No 9:11 11:10 5:5 6:5
Before treatment
Serum creatinine mg/dL 1.860.8 2.060.8 1.760.6 2.360.9
Urinary protein g/day 2.161.1 2.261.2 2.361.1 2.161.4
Selectivity index 0.2460.08 0.2960.08 0.2660.07 0.3160.09
After treatment
Serum creatinine mg/dL 2.361.1f 2.061.3 1.560.6e,f 2.561.6e
Urinary protein g/day 2.961.8a,b 1.861.6a 0.760.5b,d 2.861.7d
Selectivity index 0.2460.10g 0.2660.12 0.1860.07c 0.3360.11c,g
Quantitative data are expressed as means 6 standard deviation. The t-test and Pearson’s x2 are used for comparing data between groups.
a P , 0.05
b P , 0.002
c P , 0.002
d P , 0.005
e NS (P 5 0.073)
f P , 0.05
g P , 0.05
0.5 g/day (P , 0.001). LMW proteinuria (a1m) also de- patients with improvement in renal function in the treat-
creased significantly (91 6 55 to 33 6 30 AU/day, P , ment group, four were from the responder, and the other
0.01). Among the 11 nonresponders, there was no change four were from the nonresponder group.
in the SI, proteinuria, or serum creatinine.
Table 2 compares the data between the various groups.
DISCUSSIONAfter treatment, proteinuria in the treatment group (1.8 6
Improvement in proteinuria in patients treated with1.6 g/day) was significantly less than the control group
ACEI varies from 30 to 50% according to various series(2.9 6 1.8 g/day, P , 0.05). It was also less in the re-
[9–12]. We adopted a reduction of proteinuria of 30%sponder group (0.7 6 0.5 g/day) compared with the con-
as some patients were on a relatively short period oftrol group (2.9 6 1.8 g/day, P , 0.002). The post-treat-
treatment of six months and on a small dose of eitherment SI in the responder group (0.18 6 0.07) was better
5 mg ACEI or 50 mg of ATRA. Based on this criterion,than that of the nonresponder group (0.33 6 0.11, P ,
we studied a group of patients with IgAN, compared0.002). The post-treatment proteinuria in the responder
with a control group. About 50% of patients respondedgroup (0.7 6 0.5 g/day) was also less than the nonre-
to therapy after a mean duration of 12 months. Patientssponder group (2.8 6 1.7 g/day, P , 0.005). Serum creati-
in the treatment group had stabilization of renal function,nine was not different (1.5 6 0.6 vs. 2.5 6 1.6 mg/dL,
while renal function deteriorated in the control group.P 5 NS).
Among patients in the treatment group, the respondersFigure 1 shows the serum creatinine in the treatment
not only had a decrease in proteinuria, but there was(N 5 21) and control group (N 5 20) before and after
improvement in SI and renal function in contrast to thosetrial. The renal function in the treatment group remained
who showed no response to ACEI/ATRA therapy.stable, while that in the control group deteriorated (P ,
Hitherto, studies in relationship to ACEI therapy have0.05). Figure 2 compares the serum creatinine in the
reported improvement in proteinuria associated with re-responder (N 5 11) and nonresponder group (N 5 10)
tardation of the progression of renal failure [13, 14].before and after the trial. The responder group had im-
Ruggenenti et al documented normalization of renalprovement in renal function (P , 0.02), while there was
function in 8 out of 74 patients, and these patients contin-no change in the nonresponder group. Table 3 shows the
ued to have normal renal function over 36 months ofserial serum creatinine during the trial in eight patients in
follow-up [15]. In our study, we had 8 out of 21 patientsthe treatment group and two patients in the control
who already had documented renal impairment of atgroup who had improvement in their renal function after
least one year before starting therapy, and their renalthe trial. There were significantly more patients in the
function improved after treatment (4 from the respondertreatment group compared with the control group who
group and 4 from the nonresponder group), suggestinghad improvement in renal function (improved:not im-
proved, 8:13 vs. 2:18, x2 5 4.4, P , 0.05). Of the eight that even though proteinuria may not improve, renal
Woo et al: ACEI/ATRA therapy in IgAN 2489
Fig. 1. Comparison of the serum creatinine
before and after the trial among the patients
in the treatment (left; N 5 21; P 5 NS) and
control (right; N 5 20; P , 0.05) groups using
the paired t-test.
Fig. 2. Comparison of the serum creatinine
before and after the trial among the respond-
ers (left; N 5 10; P , 0.02) and nonresponders
(right; N 5 11; P 5 NS) in the treatment group
using paired t-test.
function may improve as in four patients in the nonre- the size of large unselective pores on the GBM [6]. A
reduction of the protein excretion rate is associated with asponder group, in the absence of any acute reversible
elements like the nephrotic state, sepsis, dehydration, slower rate of glomerular filtration rate decline in patients
with IDDM with overt nephropathy [19]. ACEI, in addi-uncontrolled hypertension, or exposure to nephrotoxic
drugs. Of the eight patients who improved their renal tion to BP control, reduces proteinuria and prevents renal
injury and progression to end-stage renal failure [20].function, three normalized their renal function (2 from
the responder group and 1 from the nonresponder group). Recent studies have also demonstrated that ACEI,
apart from remodeling the GBM (the improvement inTherapy with ACEI/ATRA probably decreases the
quantity of proteinuria in responsive patients by decreas- pore selectivity being one of the end results), may also
have beneficial effects on the mesangial cells by decreas-ing the shunt pathway through improvement of size se-
lectivity [16–18]. Morelli et al, analyzing glomerular siev- ing transforming growth factor-b (TGF-b) production,
thereby decreasing mesangial matrix production, henceing coefficients of neutral test macromolecules, reported
that in patients with IDDM, studied early in the course ameliorating the disease process in IgAN where there is
mesangial cell proliferation [21]. In addition, ATRA hasof the disease, ACEI reduced proteinuria by reducing
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Table 3. Treatment with ACEI/ATRA to improve renal function
Trial
0 3 6 9 12 15 18 21 duration
months
Treatment group (N 5 20)
Responders no.
2a 1.9 1.5 1.3 1.3 9
4a 1.6 1.5 1.5 1.4 1.1 1.1 1.1 18
5 2.0 2.3 2.7 1.8 1.9 1.9 1.6 1.7 21
6 2.9 2.6 3.5 2.5 2.6 12
Nonresponders no.
5 2.2 2.0 2.2 2.0 2.0 12
6 1.8 1.5 1.5 6
9a 1.8 1.5 1.8 1.6 1.7 1.2 1.3 18
10 2.3 1.7 1.7 1.7 1.5 12
Control group (N 5 21)
2a 2.4 2.2 1.6 1.6 1.0 12
3 4.5 3.2 3.1 2.9 9
Improved Not improved
Treatment group 8 13
Control group 2 18
Chi-square 5 4.4 P , 0.05
Data shown are serial measurement of serum creatinine (mg/dL).
a Patients who regained normal renal function
been shown to exert an antiproliferative effect on mesan- flow, glomerular filtration rate, plasma renin activity, and
plasma angiotensin II levels and did not demonstrategial proliferative glomerulonephritis [22]. This could
any significant differences. The antiproteinuric effecthelp to explain further the improvement in renal function
therefore appears to be dependent primarily on AT1in patients with IgAN on ACEI/ATRA therapy. In order
receptor-mediated pathway [27].for this to occur, the injury must be still at the stage in
While ACEI has been previously reported to be bene-which it is possible for amelioration of the renal lesions
ficial in retarding the progression of renal failure in pa-and possibly remodeling of the renal architecture. Pa-
tients with IgAN [13, 14], we now show that ATRA istients with more advanced renal disease with glomerulo-
just as effective and that in patients with renal impair-sclerosis and thickening of the GBM are less likely to
ment, there is also the possibility of normalizing renalrespond to therapy with improvement in SI and serum
function in some patients. Furthermore, we have docu-creatinine. In this respect, we found that patients with
mented that a decrease in proteinuria is due to improve-serum creatinine exceeding 3 mg/dL are less likely to
ment in glomerular permselectivity. Finally, even ifrecover renal function though therapy with ACEI/
ACEI/ATRA does not decrease proteinuria, there is stillATRA may retard their long-term progression to end-
the benefit of improvement in renal function in thosestage renal failure.
with renal impairment because ACEI/ATRA may haveLow molecular weight proteinuria has been reported
other beneficial effects on the kidneys that are not re-as a bad prognostic index in IgA nephritis [23–25]. ACEI/
lated to decrease in proteinuria alone [21, 22].ATRA therapy, apart from decreasing proteinuria, prob-
Recently, Russo et al, in a study of eight patients with
ably modifies the composition of the urinary protein, IgAN, demonstrated that the combined antiproteinuric
thus improving the SI and decreasing the LMW protein- effect of converting-enzyme inhibitor (CEI) and losartan
uria. This may explain the beneficial effects of therapy was superior to that of CEI alone or losartan alone [28].
with ACEI/ATRA in preserving renal function in pa- We examined the results of ACEI alone (N 5 8), ATRA
tients with proteinuria since proteinuria contributes to alone (N 5 8), and combination therapy with ACEI/
worsening renal function [5] and LMW proteinuria is ATRA (N 5 5) in our treated patients and found that
associated with a poor prognosis [23, 25]. there was no statistical difference in the results.
Individual antiproteinuric response to ACEI varies In conclusion, our data suggest that therapy with
depending on ACE gene polymorphism as those with ACEI/ATRA may be beneficial in patients with IgA
the D-allele of the ACE gene polymorphism respond nephritis with renal impairment and nonselective pro-
better to the antiproteinuric effect of ACEI therapy teinuria, as such patients may respond to therapy with
[11, 26]. The antiproteinuric effect of ATRA is the same improvement in glomerular permselectivity, decrease of
as that of ACEI. One study compared the effect of ACEI proteinuria, including LMW proteinuria and improve-
ment in renal function.and ATRA on blood pressure, proteinuria, renal blood
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